Study wrapper · #1019
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
La Vignera S, Condorelli RA Journal of the Endocrine Society. 2026.
DOI: 10.1210/jendso/bvag149PubMed: 42487666
Editor's note
A narrative review synthesizing pharmacogenomic data on how GLP1R and GIPR polymorphisms relate to variability in response to semaglutide and tirzepatide. The associations described are drawn largely from earlier genetic studies and remain hypothesis-generating; the authors note that population-specific prospective data are still limited. Useful as background on why individual responses differ, rather than as clinically actionable guidance.
Plain-language abstract
This review examines how genetic differences in the GLP-1 and GIP receptors may explain why people respond differently to semaglutide and tirzepatide. Certain receptor variants are associated with differences in weight loss, blood-sugar changes, and side effects such as nausea.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026